| Li, Yang |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
NCT05407246: Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis |
|
|
| Completed | 2 | 90 | RoW | Hemay005, placebo | Tianjin Hemay Pharmaceutical Co., Ltd | Active Ankylosing Spondylitis | 08/23 | 08/23 | | |
NCT05269173: Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease |
|
|
| Completed | 2 | 240 | RoW | Flos gossypii flavonoids tablet | Capital Medical University, Xinjiang Uygur Pharmaceutical Co., Ltd. | Alzheimer Disease | 08/24 | 11/24 | | |
| Kang, Yan |
NCT06351150: Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock |
|
|
| Not yet recruiting | 3 | 214 | RoW | Angiotensin II Injection, 0.9% sodium chloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Vasodilatory Shock | 06/27 | 12/27 | | |
| Huo, Lijuan |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Zhang, Liaoyun |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study |
|
|
| Recruiting | N/A | 2500 | RoW | | AstraZeneca | NASH With Fibrosis | 12/26 | 12/26 | | |
| Zhang, Liyun |
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT05269173: Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease |
|
|
| Completed | 2 | 240 | RoW | Flos gossypii flavonoids tablet | Capital Medical University, Xinjiang Uygur Pharmaceutical Co., Ltd. | Alzheimer Disease | 08/24 | 11/24 | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
NCT06400537: Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 18 | RoW | A-319 | Wuhan Union Hospital, China, ITabMed Co., Ltd. | Systemic Lupus Erythematosus | 05/25 | 05/26 | | |
NCT06056921: Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease |
|
|
| Recruiting | 1 | 24 | RoW | CD19 targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 12/25 | 08/26 | | |
| Cheng, Zhifeng |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
|
|
| Recruiting | 3 | 888 | Europe, US, RoW | Orforglipron, LY3502970, Dapagliflozin | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
|
|
| Recruiting | 3 | 600 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | OSA, Overweight or Obesity | 11/26 | 01/27 | | |
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone |
|
|
| Active, not recruiting | 3 | 520 | Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Type 2 Diabetes | 04/25 | 04/25 | | |
NCT05963022: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) |
|
|
| Completed | 3 | 168 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Type 2 Diabetes | 10/24 | 10/24 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 405 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteo Arthritis Knee | 02/26 | 03/26 | | |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight |
|
|
| Active, not recruiting | 3 | 1000 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 05/26 | 05/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events |
|
|
| Completed | 2 | 233 | Europe, Japan, US, RoW | LY3473329, Placebo | Eli Lilly and Company | Lipoprotein Disorder | 03/24 | 03/24 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
NCT06118021: A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects |
|
|
| Recruiting | 2 | 200 | RoW | HS-20094, HS-20094 injection, Placebo, Placebo injection | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Overweight and Obesity | 08/24 | 10/24 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
| Active, not recruiting | 2 | 145 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 10/24 | 01/25 | | |
| Contact, See Central |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
| Completed | 2 | 342 | Japan | VN-0200 | Daiichi Sankyo | Respiratory Syncytial Virus Infections | 04/23 | 02/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan |
|
|
| Active, not recruiting | 2 | 21 | Japan | Pexidartinib, TURALIO™, PLX3397 | Daiichi Sankyo Co., Ltd. | Tenosynovial Giant Cell Tumor | 03/23 | 05/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 120 | US, RoW | Q702, Pembrolizumab, KEYTRUDA® | Qurient Co., Ltd., Merck Sharp & Dohme LLC | Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer | 10/25 | 06/26 | | |
| Recruiting | 1/2 | 130 | US, RoW | Q901, KEYTRUDA® (pembrolizumab) | Qurient Co., Ltd., Merck Sharp & Dohme LLC | Advanced Cancer, Metastatic Cancer | 12/25 | 08/26 | | |
| Recruiting | 1/2 | 430 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor |
|
|
| Active, not recruiting | 1 | 78 | US | Q702 | Qurient Co., Ltd. | Solid Tumor, Advanced Cancer, Metastatic Cancer | 12/24 | 02/25 | | |
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 145 | Europe, Japan, US, RoW | Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced or Metastatic NSCLC | 06/25 | 06/25 | | |
|
|
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 40 | Canada, Japan, US | DS-1055a | Daiichi Sankyo Co., Ltd. | Solid Tumor, Advanced Cancer, Metastatic Solid Tumor | 06/25 | 06/25 | | |
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 280 | Japan, US, RoW | HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib | Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 06/25 | 02/26 | | |
| Recruiting | 1 | 80 | Japan | DS-1471a | Daiichi Sankyo Co., Ltd. | Advanced Solid Tumor | 06/27 | 06/27 | | |
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer |
|
|
| Completed | N/A | 225 | US | Archival tissue specimen and immunohistochemistry staining | Daiichi Sankyo, Inc. | Non-small Cell Lung Cancer | 04/23 | 04/23 | | |
| Zhao, Xianping |
NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection |
|
|
| Recruiting | 3 | 80 | RoW | Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Mental Health Issue | 03/26 | 03/26 | | |
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure |
|
|
| Recruiting | 3 | 522 | RoW | D-1553 Tablet, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non Small Cell Lung Cancer | 10/26 | 12/27 | | |
TQB2450-AL2846-III-01, NCT05922345: Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy. |
|
|
| Recruiting | 3 | 518 | RoW | TQB2450 injection, docetaxel injection matching placebo, AL2846 capsules, TQB2450 placebo, docetaxel injection, AL2846 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Non-small Cell Lung Cancer | 08/25 | 12/25 | | |
| Fu, Zili |
NCT05688696: Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus |
|
|
| Recruiting | 2 | 186 | RoW | Orelabrutinib (Low Dose), Orelabrutinib (High Dose), Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | Systemic Lupus Erythematosus, SLE | 08/25 | 05/26 | | |
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis |
|
|
| Recruiting | 2 | 180 | RoW | TQH3821 tablets 200 mg, TQH3821 tablets matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Rheumatoid Arthritis | 06/24 | 12/24 | | |
| Zhang, Meini |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
NCT04711148: A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis |
|
|
| Active, not recruiting | 2 | 160 | Europe, US, RoW | placebo, orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | Relapsing Remitting Multiple Sclerosis | 02/26 | 03/26 | | |
NCT05145361: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 1 | 45 | RoW | B001 injection, Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | NMO Spectrum Disorder | 12/25 | 12/25 | | |
| Jiang |
NCT06175351: Study to Evaluate the Pharmacokinetic Characteristics, Safety, Tolerability, and Preliminary Efficacy of 9MW1911 in Patients With Chronic Obstructive Pulmonary Disease (COPD). |
|
|
| Recruiting | 1/2 | 80 | RoW | 9MW1911, Placebo | Mabwell (Shanghai) Bioscience Co., Ltd. | Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) | 09/25 | 09/25 | | |
| Jia, Hongyan |
| Completed | 3 | 275 | RoW | GB491+ Fulvestrant, test drug + Fulvestrant, Placebo+Fulvestrant, placebo control + Fulvestrant | Genor Biopharma Co., Ltd. | Locally Advanced or Metastatic Breast Cancer | 12/22 | 03/24 | | |
LEONARDA-2, NCT05851014: A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer |
|
|
| Recruiting | 3 | 350 | RoW | GB491 combined with Letrozole, Placebo combined with Letrozole | Genor Biopharma Co., Ltd. | Breast Cancer | 01/26 | 01/27 | | |
| Li, Xinrong |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
| Feng, Yan |
| No trials found |
